Those who tested positive and did not require hospital admission received their specific therapy in a dedicated COVID-19 area managed by the physicians of the Center, ensuring personalized treatment even during the pandemic [[3]]. Blood transfusions were guaranteed for more than 200 thalassemia and SCD transfusion-dependent patients, as well as replacement therapy for PID patients. One patient with Fabry disease switched from IV enzyme replacement therapy to oral chaperon treatment (§). [Extracted from the article]